Luiz Sérgio Fernandes de Carvalho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Luiz Sérgio Fernandes de Carvalho has a total of 525 co-authors. Here are the top co-authors by number of shared publications:
- Andrei Carvalho Sposito
Department of Internal Medicine, School of Medical Sciences, State University of Campinas, Campinas, Brazil
47 shared publications - Wilson Nadruz
Department of Internal Medicine, School of Medical Sciences, State University of Campinas
19 shared publications - Filipe Azevedo Moura
Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT; VA Connecticut Healthcare System, West Haven, CT
12 shared publications Jose C. Quinaglia e Silva
Hospital de Base do Distrito Federal, Brasília, Brazil
11 shared publications- Otavio Rizzi Coelho Filho
Faculdade de Ciências Médicas, Universidade Estadual de Campinas, São Paulo, Brazil
11 shared publications - Riobaldo M. R. Cintra
State University of Campinas Medical School, Campinas, SP, Brazil
11 shared publications
Latest Publications
- Open Access
- 21 September 2026
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 10, e90863
Agreement Between a Mobile Self-Administered Comprehensive Geriatric Assessment Screening Tool and Geriatrician-Administered Assessment: Cross-Sectional Feasibility Study
Background: Comprehensive geriatric assessment (CGA) is a widely recommended, multidimensional approach for guiding clinical decision-making and management in older adults. However, its implementation remains limited by a shortage of geriatric specialists, the complexity of geriatric care, and the increasing demands of an aging population. Mobile self-administered tools offer a potential strategy to expand access to multidimensional geriatric evaluation, particularly in resource-limited settings. Objective: This study aimed to evaluate the feasibility and agreement of a mobile self-administered CGA screening tool compared with geriatrician-administered assessments among inpatient and outpatient older adults in Brazil. Methods: This cross-sectional study included 80 older adults recruited from inpatient and outpatient geriatric clinics in Brasília, Brazil. Participants completed a mobile CGA, which incorporated validated instruments covering functional status (Vulnerable Elders Survey–13 [VES-13]), cognition (Cognitive Change Questionnaire–8 [CCQ-8]), depressive symptoms (5-item Geriatric Depression Scale [GDS-5]), nutritional status (Mini Nutritional Assessment [MNA]), frailty (G8 screening tool), social support (Gijón Scale), falls, and vision and hearing. Within 48 hours, a geriatrician independently performed a geriatrician-administered CGA using the same instruments. Agreement between the 2 assessment methods was evaluated using Wilcoxon signed-rank tests, Spearman correlation coefficients, intraclass correlation coefficients (ICCs), and Cohen κ coefficients for categorical variables. Results: Participants had a mean age of 70 (SD 7) years; 58.8% (47/80) were female, and 65% (52/80) had ≤8 years of education. The mean completion time for the self-administered CGA was 18.5 (SD 7.5) minutes. Most participants rated the tool as easy or very easy to use (65/80, 81.3%) and reported satisfaction with the assessment process (n=79, 98.8%). High concordance was observed between the self-administered and geriatrician-administered CGA versions for most domains. Cohen κ coefficients demonstrated strong agreement for falls (κ=0.878; P <.001), hearing impairment (κ=0.826), and vision impairment (κ=0.634). No significant differences were observed between the 2 assessment methods for functional status (VES-13), frailty screening (G8), depressive symptoms (GDS-5), and cognition (CCQ-8). Nutritional status and social vulnerability showed lower concordance than other CGA domains. Among inpatients, significant discrepancies were identified in both nutritional scores and Gijón social risk scores ( P ≤.05), with participants reporting greater perceived vulnerability. For outpatients, significant differences were observed for nutritional status (MNA; P=.02) and frailty screening (G8; P=.046). Conclusions: A mobile self-administered CGA demonstrated good feasibility, high user satisfaction, and substantial agreement with geriatrician-administered assessments across multiple geriatric domains. The tool may support geriatric screening and triage in settings with limited specialist availability, particularly when used as a complement to comprehensive clinical assessment.
- 21 September 2026
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 10, e90863
Open AccessAgreement Between a Mobile Self-Administered Comprehensive Geriatric Assessment Screening Tool and Geriatrician-Administered Assessment: Cross-Sectional Feasibility Study
Background: Comprehensive geriatric assessment (CGA) is a widely recommended, multidimensional approach for guiding clinical decision-making and management in older adults. However, its implementation remains limited by a shortage of geriatric specialists, the complexity of geriatric care, and the increasing demands of an aging population. Mobile self-administered tools offer a potential strategy to expand access to multidimensional geriatric evaluation, particularly in resource-limited settings. Objective: This study aimed to evaluate the feasibility and agreement of a mobile self-administered CGA screening tool compared with geriatrician-administered assessments among inpatient and outpatient older adults in Brazil. Methods: This cross-sectional study included 80 older adults recruited from inpatient and outpatient geriatric clinics in Brasília, Brazil. Participants completed a mobile CGA, which incorporated validated instruments covering functional status (Vulnerable Elders Survey–13 [VES-13]), cognition (Cognitive Change Questionnaire–8 [CCQ-8]), depressive symptoms (5-item Geriatric Depression Scale [GDS-5]), nutritional status (Mini Nutritional Assessment [MNA]), frailty (G8 screening tool), social support (Gijón Scale), falls, and vision and hearing. Within 48 hours, a geriatrician independently performed a geriatrician-administered CGA using the same instruments. Agreement between the 2 assessment methods was evaluated using Wilcoxon signed-rank tests, Spearman correlation coefficients, intraclass correlation coefficients (ICCs), and Cohen κ coefficients for categorical variables. Results: Participants had a mean age of 70 (SD 7) years; 58.8% (47/80) were female, and 65% (52/80) had ≤8 years of education. The mean completion time for the self-administered CGA was 18.5 (SD 7.5) minutes. Most participants rated the tool as easy or very easy to use (65/80, 81.3%) and reported satisfaction with the assessment process (n=79, 98.8%). High concordance was observed between the self-administered and geriatrician-administered CGA versions for most domains. Cohen κ coefficients demonstrated strong agreement for falls (κ=0.878; P <.001), hearing impairment (κ=0.826), and vision impairment (κ=0.634). No significant differences were observed between the 2 assessment methods for functional status (VES-13), frailty screening (G8), depressive symptoms (GDS-5), and cognition (CCQ-8). Nutritional status and social vulnerability showed lower concordance than other CGA domains. Among inpatients, significant discrepancies were identified in both nutritional scores and Gijón social risk scores ( P ≤.05), with participants reporting greater perceived vulnerability. For outpatients, significant differences were observed for nutritional status (MNA; P=.02) and frailty screening (G8; P=.046). Conclusions: A mobile self-administered CGA demonstrated good feasibility, high user satisfaction, and substantial agreement with geriatrician-administered assessments across multiple geriatric domains. The tool may support geriatric screening and triage in settings with limited specialist availability, particularly when used as a complement to comprehensive clinical assessment.
- Open Access
- 30 July 2026
- Published by Elsevier in JSAMS Plus
- Vol. 8
Exercise-based rehabilitation with or without blood flow restriction in individuals with heart failure: Protocol for the rehab-washout HF trial
- 30 July 2026
- Published by Elsevier in JSAMS Plus
- Vol. 8
Open AccessExercise-based rehabilitation with or without blood flow restriction in individuals with heart failure: Protocol for the rehab-washout HF trial
- Open Access
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
Obesity as a Vertical Risk Amplifier in STEMI Across CKM Syndrome Stages: Accelerated Onset and Impaired Myocardial Reperfusion Despite Timely Intervention
Background and Objective: The Cardiovascular-Kidney-Metabolic (CKM) syndrome framework provides a meaningful risk stratification strategy, yet obesity’s independent prognostic role in ST-elevation myocardial infarction (STEMI) remains debated. We investigated the association of obesity with clinical outcomes across CKM syndrome stages within the Brazilian B-Care cohort.Method: This study evaluated 4,004 consecutive individuals hospitalized for STEMI in the Federal District, Brazil (2009–2019). Patients were stratified into CKM stages (0/1, 2/3, and 4) and compared by the presence of obesity. Primary outcomes included all-cause mortality and major adverse cardiovascular events (MACE).Results: Obesity (31% of the cohort) accelerated STEMI onset by approximately 4.2 years across all CKM stages. Despite comparable reperfusion process times (p>0.05), obese patients achieved significantly poorer myocardial reperfusion quality, with lower rates of TIMI 3 flow and myocardial blush grade 3 (TIMI 3 in CKM 4: 74.5% vs. 82.1%; p < 0.05). Obesity consistently amplified mortality risk, ranging from aHR 2.7 (CKM 1) to 6.14 (CKM 4). Notably, obese patients in intermediate CKM stages (2/3) faced mortality risks comparable to non-obese patients with overt disease (CKM 4).Conclusion: Obesity functions as a vertical risk amplifier across the CKM spectrum, accelerating disease onset and significantly worsening long-term prognosis. The dissociation between adequate procedural timing and inferior tissue-level reperfusion highlights a heightened ischemic vulnerability in obese patients. Therefore, obesity must be prioritized as a primary, independent driver of cardiovascular risk that necessitates targeted microvascular protection strategies beyond conventional risk scores
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessObesity as a Vertical Risk Amplifier in STEMI Across CKM Syndrome Stages: Accelerated Onset and Impaired Myocardial Reperfusion Despite Timely Intervention
Background and Objective: The Cardiovascular-Kidney-Metabolic (CKM) syndrome framework provides a meaningful risk stratification strategy, yet obesity’s independent prognostic role in ST-elevation myocardial infarction (STEMI) remains debated. We investigated the association of obesity with clinical outcomes across CKM syndrome stages within the Brazilian B-Care cohort.Method: This study evaluated 4,004 consecutive individuals hospitalized for STEMI in the Federal District, Brazil (2009–2019). Patients were stratified into CKM stages (0/1, 2/3, and 4) and compared by the presence of obesity. Primary outcomes included all-cause mortality and major adverse cardiovascular events (MACE).Results: Obesity (31% of the cohort) accelerated STEMI onset by approximately 4.2 years across all CKM stages. Despite comparable reperfusion process times (p>0.05), obese patients achieved significantly poorer myocardial reperfusion quality, with lower rates of TIMI 3 flow and myocardial blush grade 3 (TIMI 3 in CKM 4: 74.5% vs. 82.1%; p < 0.05). Obesity consistently amplified mortality risk, ranging from aHR 2.7 (CKM 1) to 6.14 (CKM 4). Notably, obese patients in intermediate CKM stages (2/3) faced mortality risks comparable to non-obese patients with overt disease (CKM 4).Conclusion: Obesity functions as a vertical risk amplifier across the CKM spectrum, accelerating disease onset and significantly worsening long-term prognosis. The dissociation between adequate procedural timing and inferior tissue-level reperfusion highlights a heightened ischemic vulnerability in obese patients. Therefore, obesity must be prioritized as a primary, independent driver of cardiovascular risk that necessitates targeted microvascular protection strategies beyond conventional risk scores
- Open Access
- 29 April 2026
- Published by Wiley in Journal of Evaluation in Clinical Practice
- Vol. 32 (4) , e70456
A Remote Chronic Disease Management Program to Improve Cardiovascular and Metabolic Outcomes in a Diverse Community‐Based Diabetic Population: Study Design of the TAMIS Trial
Introduction: Cardiovascular and cerebrovascular diseases are projected to expand in the coming decades as the main cause of death. This study outlines the escalating burden of cardiovascular diseases in low‐ and middle‐income countries (LMICs), particularly in Latin America (LA), which is expected to surpass that of other high‐population regions. Despite advances in prevention strategies, adherence to therapeutic goals remains a global challenge, especially in LMICs where control rates are notably low for conditions such as hypertension, type 2 diabetes mellitus (DM2), and dyslipidemia. Emerging evidence from LMICs supports the feasibility and effectiveness of telehealth interventions for cardiometabolic disease management in primary care. Aims: To address these challenges, a remote chronic disease management program has been developed to optimize risk factor control through standardized medical protocols and task automation. Methods: This is an open‐label randomized and decentralized clinical trial describing the design and methodology of the TAMIS program, which will assess its impact on community‐dwelling diabetic subjects with uncontrolled HBA1c and uncontrolled LDL‐C and/or blood pressure. Individuals will be randomized to usual care or remote care and followed for 84 weeks. Remote monitoring offers a practical response to the limited capacity of LMIC health systems to ensure sustained follow‐up and continuity of care for chronic conditions. The primary endpoint is a win‐ratio of hierarchical events, including all‐cause deaths and the frequency of all‐cause hospitalizations. The secondary endpoints include control of HbA1c, LDL‐C and blood pressure according to clinical guidelines, as well as patient‐reported outcomes and clinical parameters, including blood pressure, glycemic control, and LDL cholesterol levels. Subgroup analyses will explore the impact of demographics and clinical characteristics on treatment outcomes. Overall, the study aims to improve health care delivery, enhance patient education, and foster collaboration between patients and health care providers to mitigate the growing burden of cardiovascular diseases in LMICs.
- 29 April 2026
- Published by Wiley in Journal of Evaluation in Clinical Practice
- Vol. 32 (4) , e70456
Open AccessA Remote Chronic Disease Management Program to Improve Cardiovascular and Metabolic Outcomes in a Diverse Community‐Based Diabetic Population: Study Design of the TAMIS Trial
Introduction: Cardiovascular and cerebrovascular diseases are projected to expand in the coming decades as the main cause of death. This study outlines the escalating burden of cardiovascular diseases in low‐ and middle‐income countries (LMICs), particularly in Latin America (LA), which is expected to surpass that of other high‐population regions. Despite advances in prevention strategies, adherence to therapeutic goals remains a global challenge, especially in LMICs where control rates are notably low for conditions such as hypertension, type 2 diabetes mellitus (DM2), and dyslipidemia. Emerging evidence from LMICs supports the feasibility and effectiveness of telehealth interventions for cardiometabolic disease management in primary care. Aims: To address these challenges, a remote chronic disease management program has been developed to optimize risk factor control through standardized medical protocols and task automation. Methods: This is an open‐label randomized and decentralized clinical trial describing the design and methodology of the TAMIS program, which will assess its impact on community‐dwelling diabetic subjects with uncontrolled HBA1c and uncontrolled LDL‐C and/or blood pressure. Individuals will be randomized to usual care or remote care and followed for 84 weeks. Remote monitoring offers a practical response to the limited capacity of LMIC health systems to ensure sustained follow‐up and continuity of care for chronic conditions. The primary endpoint is a win‐ratio of hierarchical events, including all‐cause deaths and the frequency of all‐cause hospitalizations. The secondary endpoints include control of HbA1c, LDL‐C and blood pressure according to clinical guidelines, as well as patient‐reported outcomes and clinical parameters, including blood pressure, glycemic control, and LDL cholesterol levels. Subgroup analyses will explore the impact of demographics and clinical characteristics on treatment outcomes. Overall, the study aims to improve health care delivery, enhance patient education, and foster collaboration between patients and health care providers to mitigate the growing burden of cardiovascular diseases in LMICs.
- Open Access
- 1 January 2026
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 123 (9)
Individual Effects of Angiotensin II Receptor Blockers on Major Adverse Cardiovascular Events: A Systematic Review and Network Meta-Analysis
Background Angiotensin II receptor blockers (ARBs) antagonize the AT1 receptor and are effective antihypertensives. Modest differences in blood pressure-lowering efficacy have been reported, reflecting variations in pharmacokinetics, receptor binding, duration of action, and potential pleiotropic effects. However, data on their comparative effects on cardiovascular outcomes in patients are scarce. Objective To assess the effects of ARBs on MACE, hospitalization for heart failure (HHF), and all-cause mortality in randomized trials not primarily designed to evaluate heart failure (HF). Methods MEDLINE/PubMed, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov databases were searched until May 2025. Published RCTs reporting major adverse cardiovascular events (MACE), HHF or all-cause death, involving ARBs, with at least 100 individuals per arm and ≥12 months of follow-up, were included. Studies focusing primarily on patients with existing HF were excluded. Incidence rates of HHF, MACE, and all-cause death. A random-effects network meta-analysis including 27 RCTs and 702,584 patient-years was performed. Results Candesartan reduced MACE versus placebo (OR 0.79; 95% CI, 0.63–0.97; SUCRA=0.85), ranking highest among ARBs, while telmisartan showed a smaller but significant reduction (OR 0.90; 95% CI, 0.80–0.99; SUCRA=0.61). The analysis relied on study-level data; included moderately sparse treatment networks with predominantly indirect comparisons between ARBs. Conclusion This network meta-analysis in patients without baseline HF indicates that candesartan and telmisartan reduce MACE, suggesting clinically meaningful differences among ARBs. Given the predominantly indirect nature of several comparisons, these findings should be interpreted cautiously.
- 1 January 2026
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 123 (9)
Open AccessIndividual Effects of Angiotensin II Receptor Blockers on Major Adverse Cardiovascular Events: A Systematic Review and Network Meta-Analysis
Background Angiotensin II receptor blockers (ARBs) antagonize the AT1 receptor and are effective antihypertensives. Modest differences in blood pressure-lowering efficacy have been reported, reflecting variations in pharmacokinetics, receptor binding, duration of action, and potential pleiotropic effects. However, data on their comparative effects on cardiovascular outcomes in patients are scarce. Objective To assess the effects of ARBs on MACE, hospitalization for heart failure (HHF), and all-cause mortality in randomized trials not primarily designed to evaluate heart failure (HF). Methods MEDLINE/PubMed, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov databases were searched until May 2025. Published RCTs reporting major adverse cardiovascular events (MACE), HHF or all-cause death, involving ARBs, with at least 100 individuals per arm and ≥12 months of follow-up, were included. Studies focusing primarily on patients with existing HF were excluded. Incidence rates of HHF, MACE, and all-cause death. A random-effects network meta-analysis including 27 RCTs and 702,584 patient-years was performed. Results Candesartan reduced MACE versus placebo (OR 0.79; 95% CI, 0.63–0.97; SUCRA=0.85), ranking highest among ARBs, while telmisartan showed a smaller but significant reduction (OR 0.90; 95% CI, 0.80–0.99; SUCRA=0.61). The analysis relied on study-level data; included moderately sparse treatment networks with predominantly indirect comparisons between ARBs. Conclusion This network meta-analysis in patients without baseline HF indicates that candesartan and telmisartan reduce MACE, suggesting clinically meaningful differences among ARBs. Given the predominantly indirect nature of several comparisons, these findings should be interpreted cautiously.
- Open Access
- 1 January 2026
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 123 (9)
Efeitos dos Diferentes Bloqueadores dos Receptores da Angiotensina II Sobre Eventos Cardiovasculares Adversos Maiores: Revisão Sistemática e Metanálise em Rede
Resumo Fundamento Os bloqueadores dos receptores da angiotensina II (BRAs) antagonizam o receptor AT1 e são anti-hipertensivos eficazes. Diferenças modestas na eficácia da redução da pressão arterial têm sido relatadas, refletindo variações na farmacocinética, na ligação ao receptor, na duração da ação e em potenciais efeitos pleiotrópicos. Entretanto, os dados sobre seus efeitos comparativos nos desfechos cardiovasculares em pacientes são escassos. Objetivo Avaliar os efeitos dos BRAs sobre eventos cardiovasculares adversos maiores (MACE), hospitalização por insuficiência cardíaca (HHF) e mortalidade por todas as causas em ensaios randomizados não delineados primariamente para avaliar insuficiência cardíaca (IC). Métodos As bases de dados MEDLINE/PubMed, Cochrane Central Register of Controlled Trials e ClinicalTrials.gov foram pesquisadas até maio de 2025. Foram incluídos ensaios clínicos randomizados publicados que relataram eventos cardiovasculares adversos maiores (MACE), HHF ou morte por todas as causas, envolvendo BRAs, com pelo menos 100 indivíduos por braço e acompanhamento ≥12 meses. Estudos focados principalmente em pacientes com IC preexistente foram excluídos. Taxas de incidência de HHF, MACE e morte por todas as causas. Foi realizada uma metanálise em rede de efeitos aleatórios, incluindo 27 ensaios clínicos randomizados e 702.584 pacientes-ano. Resultados O candesartana reduziu MACE em comparação ao placebo (OR 0,79; IC 95%, 0,63–0,97; SUCRA=0,85), apresentando a melhor classificação entre os BRAs, enquanto a telmisartana demonstrou uma redução menor, porém significativa (OR 0,90; IC 95%, 0,80–0,99; SUCRA=0,61). A análise baseou-se em dados em nível de estudo; as redes de tratamentos incluídas eram moderadamente esparsas, com comparações predominantemente indiretas entre os BRAs. Conclusão Esta metanálise em rede, realizada em pacientes sem IC basal, indica que a candesartana e a telmisartana reduzem MACE, sugerindo diferenças clinicamente relevantes entre os BRAs. Considerando a natureza predominantemente indireta de várias comparações, esses achados devem ser interpretados com cautela.
- 1 January 2026
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 123 (9)
Open AccessEfeitos dos Diferentes Bloqueadores dos Receptores da Angiotensina II Sobre Eventos Cardiovasculares Adversos Maiores: Revisão Sistemática e Metanálise em Rede
Resumo Fundamento Os bloqueadores dos receptores da angiotensina II (BRAs) antagonizam o receptor AT1 e são anti-hipertensivos eficazes. Diferenças modestas na eficácia da redução da pressão arterial têm sido relatadas, refletindo variações na farmacocinética, na ligação ao receptor, na duração da ação e em potenciais efeitos pleiotrópicos. Entretanto, os dados sobre seus efeitos comparativos nos desfechos cardiovasculares em pacientes são escassos. Objetivo Avaliar os efeitos dos BRAs sobre eventos cardiovasculares adversos maiores (MACE), hospitalização por insuficiência cardíaca (HHF) e mortalidade por todas as causas em ensaios randomizados não delineados primariamente para avaliar insuficiência cardíaca (IC). Métodos As bases de dados MEDLINE/PubMed, Cochrane Central Register of Controlled Trials e ClinicalTrials.gov foram pesquisadas até maio de 2025. Foram incluídos ensaios clínicos randomizados publicados que relataram eventos cardiovasculares adversos maiores (MACE), HHF ou morte por todas as causas, envolvendo BRAs, com pelo menos 100 indivíduos por braço e acompanhamento ≥12 meses. Estudos focados principalmente em pacientes com IC preexistente foram excluídos. Taxas de incidência de HHF, MACE e morte por todas as causas. Foi realizada uma metanálise em rede de efeitos aleatórios, incluindo 27 ensaios clínicos randomizados e 702.584 pacientes-ano. Resultados O candesartana reduziu MACE em comparação ao placebo (OR 0,79; IC 95%, 0,63–0,97; SUCRA=0,85), apresentando a melhor classificação entre os BRAs, enquanto a telmisartana demonstrou uma redução menor, porém significativa (OR 0,90; IC 95%, 0,80–0,99; SUCRA=0,61). A análise baseou-se em dados em nível de estudo; as redes de tratamentos incluídas eram moderadamente esparsas, com comparações predominantemente indiretas entre os BRAs. Conclusão Esta metanálise em rede, realizada em pacientes sem IC basal, indica que a candesartana e a telmisartana reduzem MACE, sugerindo diferenças clinicamente relevantes entre os BRAs. Considerando a natureza predominantemente indireta de várias comparações, esses achados devem ser interpretados com cautela.
- Open Access
- 1 January 2026
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 123 (7)
Sacubitril/Valsartana versus Enalapril ou Losartana em Doses Máximas na Insuficiência Cardíaca com Fração de Ejeção Reduzida: Dados de Mundo Real
Resumo Fundamento: Sacubitril/valsartana reduziu a mortalidade e as hospitalizações em pacientes com insuficiência cardíaca com fração de ejeção reduzida (ICFEr) em comparação com enalapril em estudos clínicos pivotais. No entanto, os dados de mundo real sob doses otimizadas continuam limitados. Objetivo: Comparar os desfechos de pacientes com ICFEr tratados com sacubitril/valsartana versus enalapril ou losartana nas doses máximas recomendadas pelas diretrizes. Métodos: Analisamos dados de uma coorte observacional de insuficiência cardíaca (n = 2.314), incluindo pacientes atendidos entre agosto de 2010 e setembro de 2024 em seis hospitais públicos de uma grande área metropolitana. A análise primária incluiu 254 pacientes com ICFEr que receberam as doses máximas recomendadas pelas diretrizes dos medicamentos investigados. Uma análise de sensibilidade incluiu 452 pacientes que receberam quaisquer doses submáximas. O desfecho primário foi a combinação de hospitalização ou óbito. As diferenças basais foram ajustadas por meio do pareamento por escore de propensão. Foram considerados significativos valores de p < 0,05. Resultados: Entre 254 pacientes com ICFEr (idade média de 63,6 ± 12,3 anos, 61,4% do sexo masculino), 115 receberam sacubitril/valsartana 97/103 mg duas vezes ao dia, 33 enalapril 20 mg duas vezes ao dia e 106 losartana 100 mg ao dia. Durante um seguimento mediano de 23,9 meses (intervalo interquartil 11,9–41,1), ocorreram 70 eventos do desfecho primário (56 primeiras hospitalizações e 32 óbitos). Em comparação com doses equivalentes de enalapril ou losartana, sacubitril/valsartana não foi associado a reduções significativas na combinação de hospitalização ou mortalidade (odds ratio 0,650, intervalo de confiança de 95% 0,354–1,195, p = 0,165), mas foi associado à melhora do estado funcional (odds ratio 3,902, intervalo de confiança de 95% 1,745–8,726, p = 0,001). Conclusão: O presente estudo de mundo real não demonstrou reduções significativas de hospitalização ou mortalidade com sacubitril/valsartana em comparação a enalapril ou losartana nas doses máximas recomendadas pelas diretrizes; no entanto, sacubitril/valsartana foi associado à melhora da classe funcional.
- 1 January 2026
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 123 (7)
Open AccessSacubitril/Valsartana versus Enalapril ou Losartana em Doses Máximas na Insuficiência Cardíaca com Fração de Ejeção Reduzida: Dados de Mundo Real
Resumo Fundamento: Sacubitril/valsartana reduziu a mortalidade e as hospitalizações em pacientes com insuficiência cardíaca com fração de ejeção reduzida (ICFEr) em comparação com enalapril em estudos clínicos pivotais. No entanto, os dados de mundo real sob doses otimizadas continuam limitados. Objetivo: Comparar os desfechos de pacientes com ICFEr tratados com sacubitril/valsartana versus enalapril ou losartana nas doses máximas recomendadas pelas diretrizes. Métodos: Analisamos dados de uma coorte observacional de insuficiência cardíaca (n = 2.314), incluindo pacientes atendidos entre agosto de 2010 e setembro de 2024 em seis hospitais públicos de uma grande área metropolitana. A análise primária incluiu 254 pacientes com ICFEr que receberam as doses máximas recomendadas pelas diretrizes dos medicamentos investigados. Uma análise de sensibilidade incluiu 452 pacientes que receberam quaisquer doses submáximas. O desfecho primário foi a combinação de hospitalização ou óbito. As diferenças basais foram ajustadas por meio do pareamento por escore de propensão. Foram considerados significativos valores de p < 0,05. Resultados: Entre 254 pacientes com ICFEr (idade média de 63,6 ± 12,3 anos, 61,4% do sexo masculino), 115 receberam sacubitril/valsartana 97/103 mg duas vezes ao dia, 33 enalapril 20 mg duas vezes ao dia e 106 losartana 100 mg ao dia. Durante um seguimento mediano de 23,9 meses (intervalo interquartil 11,9–41,1), ocorreram 70 eventos do desfecho primário (56 primeiras hospitalizações e 32 óbitos). Em comparação com doses equivalentes de enalapril ou losartana, sacubitril/valsartana não foi associado a reduções significativas na combinação de hospitalização ou mortalidade (odds ratio 0,650, intervalo de confiança de 95% 0,354–1,195, p = 0,165), mas foi associado à melhora do estado funcional (odds ratio 3,902, intervalo de confiança de 95% 1,745–8,726, p = 0,001). Conclusão: O presente estudo de mundo real não demonstrou reduções significativas de hospitalização ou mortalidade com sacubitril/valsartana em comparação a enalapril ou losartana nas doses máximas recomendadas pelas diretrizes; no entanto, sacubitril/valsartana foi associado à melhora da classe funcional.
- Open Access
- 1 January 2026
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 123 (7)
Sacubitril/Valsartan versus Enalapril or Losartan at Maximum Doses in Heart Failure with Reduced Ejection Fraction: Real-World Data
Background: Sacubitril/valsartan reduced mortality and hospitalizations in patients with heart failure with reduced ejection fraction (HFrEF) compared to enalapril in pivotal clinical trials. However, real-world data under optimized dosing remain limited. Objective: To compare the outcomes of HFrEF patients treated with sacubitril/valsartan versus either enalapril or losartan at guideline-recommended maximum dosages. Methods: We analyzed data from an observational heart failure cohort (n = 2,314) including patients receiving care between August 2010 and September 2024 at six public hospitals in a large metropolitan area. The primary analysis included 254 HFrEF patients receiving the guideline-recommended maximum dosages of the investigated drugs. A sensitivity analysis included 452 patients receiving any submaximal dosages. The primary outcome was combined hospitalization or death. Baseline differences were adjusted using propensity score matching. A p-value < 0.05 was considered significant. Results: Among 254 HFrEF patients (mean age 63.6 ± 12.3 years, 61.4% male), 115 received sacubitril/valsartan 97/103mg twice daily, 33 enalapril 20 mg twice daily, and 106 losartan 100 mg daily. Over the median follow-up of 23.9 months (interquartile range 11.9–41.1), there were 70 primary endpoint events (56 first hospitalizations, 32 deaths). Compared to equivalent dosages of enalapril or losartan, sacubitril/valsartan was not associated with significant reductions in combined hospitalization or death (odds ratio 0.650, 95% confidence interval 0.354–1.195, p = 0.165), but it was associated with functional status improvement (odds ratio 3.902, 95% confidence interval 1.745–8.726, p = 0.001). Conclusion: This real-world study did not demonstrate significant reductions in hospitalization or mortality for sacubitril/valsartan compared with enalapril or losartan at guideline-recommended maximum dosages; however, sacubitril/valsartan was associated with improved functional status.
- 1 January 2026
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 123 (7)
Open AccessSacubitril/Valsartan versus Enalapril or Losartan at Maximum Doses in Heart Failure with Reduced Ejection Fraction: Real-World Data
Background: Sacubitril/valsartan reduced mortality and hospitalizations in patients with heart failure with reduced ejection fraction (HFrEF) compared to enalapril in pivotal clinical trials. However, real-world data under optimized dosing remain limited. Objective: To compare the outcomes of HFrEF patients treated with sacubitril/valsartan versus either enalapril or losartan at guideline-recommended maximum dosages. Methods: We analyzed data from an observational heart failure cohort (n = 2,314) including patients receiving care between August 2010 and September 2024 at six public hospitals in a large metropolitan area. The primary analysis included 254 HFrEF patients receiving the guideline-recommended maximum dosages of the investigated drugs. A sensitivity analysis included 452 patients receiving any submaximal dosages. The primary outcome was combined hospitalization or death. Baseline differences were adjusted using propensity score matching. A p-value < 0.05 was considered significant. Results: Among 254 HFrEF patients (mean age 63.6 ± 12.3 years, 61.4% male), 115 received sacubitril/valsartan 97/103mg twice daily, 33 enalapril 20 mg twice daily, and 106 losartan 100 mg daily. Over the median follow-up of 23.9 months (interquartile range 11.9–41.1), there were 70 primary endpoint events (56 first hospitalizations, 32 deaths). Compared to equivalent dosages of enalapril or losartan, sacubitril/valsartan was not associated with significant reductions in combined hospitalization or death (odds ratio 0.650, 95% confidence interval 0.354–1.195, p = 0.165), but it was associated with functional status improvement (odds ratio 3.902, 95% confidence interval 1.745–8.726, p = 0.001). Conclusion: This real-world study did not demonstrate significant reductions in hospitalization or mortality for sacubitril/valsartan compared with enalapril or losartan at guideline-recommended maximum dosages; however, sacubitril/valsartan was associated with improved functional status.
- Open Access
Sacubitril-valsartan Versus Enalapril or Losartan at Guideline-Recommended Maximum Dosages in Heart Failure with Reduced Ejection Fraction: Real-World Results from the BEAT-HF Cohort
Background: Sacubitril-valsartan reduced mortality and hospitalizations in patients with heart failure with reduced ejection fraction (HFrEF) compared to enalapril in pivotal clinical trials. However, these studies used suboptimal dosages of enalapril, potentially limiting their findings. Objective: To compare the outcomes of HFrEF patients treated with sacubitril-valsartan versus either enalapril or losartan at guideline-recommended maximum dosages. Methods: We analyzed data from BEAT-HF, an observational cohort of 2,314 HF patients who received care between Aug/2010 and Jan/2024 at six public hospitals in the Brasília, Brazil. The primary analysis included 254 HFrEF patients receiving the guideline-recommended maximum dosages of the investigated drugs. A sensitivity analysis included 452 patients receiving any sub-maximum dosages. The primary outcome was combined hospitalization or death. Baseline differences were adjusted using propensity score matching. Results: Among 254 HFrEF patients (mean age 63.6±12.3 years, 61.4% male), 115 received sacubitril-valsartan 97/103mg twice daily, 33 enalapril 20mg twice daily, and 106 losartan 100mg daily. Over the median follow-up of 23.9 months [IQR 11.9 – 41.1], there were 70 primary endpoint events (56 first hospitalizations, 32 deaths). Compared to equivalent dosages of enalapril or losartan, sacubitril-valsartan was not associated with significantly reductions in combined hospitalization or death (OR 0.650, 95%CI 0.354 – 1.195, p=0.165), but it was strongly associated with functional status improvement (OR 3.902, 95%CI 1.745 – 8.726, p=0.001). Conclusion: This real-world study wasn’t able to support significant reductions in hospitalization or mortality for sacubitril-valsartan compared with enalapril or losartan at guideline-recommended maximum dosages, suggesting that its benefits may be more modest than previously reported.
Open AccessSacubitril-valsartan Versus Enalapril or Losartan at Guideline-Recommended Maximum Dosages in Heart Failure with Reduced Ejection Fraction: Real-World Results from the BEAT-HF Cohort
Background: Sacubitril-valsartan reduced mortality and hospitalizations in patients with heart failure with reduced ejection fraction (HFrEF) compared to enalapril in pivotal clinical trials. However, these studies used suboptimal dosages of enalapril, potentially limiting their findings. Objective: To compare the outcomes of HFrEF patients treated with sacubitril-valsartan versus either enalapril or losartan at guideline-recommended maximum dosages. Methods: We analyzed data from BEAT-HF, an observational cohort of 2,314 HF patients who received care between Aug/2010 and Jan/2024 at six public hospitals in the Brasília, Brazil. The primary analysis included 254 HFrEF patients receiving the guideline-recommended maximum dosages of the investigated drugs. A sensitivity analysis included 452 patients receiving any sub-maximum dosages. The primary outcome was combined hospitalization or death. Baseline differences were adjusted using propensity score matching. Results: Among 254 HFrEF patients (mean age 63.6±12.3 years, 61.4% male), 115 received sacubitril-valsartan 97/103mg twice daily, 33 enalapril 20mg twice daily, and 106 losartan 100mg daily. Over the median follow-up of 23.9 months [IQR 11.9 – 41.1], there were 70 primary endpoint events (56 first hospitalizations, 32 deaths). Compared to equivalent dosages of enalapril or losartan, sacubitril-valsartan was not associated with significantly reductions in combined hospitalization or death (OR 0.650, 95%CI 0.354 – 1.195, p=0.165), but it was strongly associated with functional status improvement (OR 3.902, 95%CI 1.745 – 8.726, p=0.001). Conclusion: This real-world study wasn’t able to support significant reductions in hospitalization or mortality for sacubitril-valsartan compared with enalapril or losartan at guideline-recommended maximum dosages, suggesting that its benefits may be more modest than previously reported.